Natural killer cell mediated pathogenesis determines outcome of central nervous system infection with Venezuelan equine encephalitis virus in C3H/HeN mice

Katherine Taylor, Olga Kolokoltsova, Michael Patterson, Allison Poussard, Jennifer Smith, D. Mark Estes, Slobodan Paessler

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

TC83 is a human vaccine with investigational new drug status and is used as a prototype Venezuelan equine encephalitis virus for pathogenesis and antiviral research. Differing from other experimental models, the virus causes high titer infection in the brain and 90-100% mortality in the C3H/HeN murine model. To better characterize the susceptibility to disease development in C3H/HeN mice, we have analyzed the gene transcriptomes and cytokine production in the brains of infected mice. Our analysis indicated the potential importance of natural killer cells in the encephalitic disease development. This paper describes for the first time a pathogenic role for natural killer cells in VEEV encephalitis.

Original languageEnglish (US)
Pages (from-to)4095-4105
Number of pages11
JournalVaccine
Volume30
Issue number27
DOIs
StatePublished - Jun 8 2012

Fingerprint

Venezuelan Equine Encephalitis Viruses
Venezuelan equine encephalitis virus
Central Nervous System Infections
Inbred C3H Mouse
natural killer cells
Natural Killer Cells
central nervous system
pathogenesis
Investigational Drugs
brain
new drugs
Disease Susceptibility
mice
Brain
Encephalitis
encephalitis
Transcriptome
prototypes
transcriptome
infection

Keywords

  • Alphavirus
  • Encephalitis
  • Immunology
  • Natural killer cells
  • VEEV

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Natural killer cell mediated pathogenesis determines outcome of central nervous system infection with Venezuelan equine encephalitis virus in C3H/HeN mice. / Taylor, Katherine; Kolokoltsova, Olga; Patterson, Michael; Poussard, Allison; Smith, Jennifer; Estes, D. Mark; Paessler, Slobodan.

In: Vaccine, Vol. 30, No. 27, 08.06.2012, p. 4095-4105.

Research output: Contribution to journalArticle

Taylor, Katherine ; Kolokoltsova, Olga ; Patterson, Michael ; Poussard, Allison ; Smith, Jennifer ; Estes, D. Mark ; Paessler, Slobodan. / Natural killer cell mediated pathogenesis determines outcome of central nervous system infection with Venezuelan equine encephalitis virus in C3H/HeN mice. In: Vaccine. 2012 ; Vol. 30, No. 27. pp. 4095-4105.
@article{8810706a1eee434a9e06d81489229bfa,
title = "Natural killer cell mediated pathogenesis determines outcome of central nervous system infection with Venezuelan equine encephalitis virus in C3H/HeN mice",
abstract = "TC83 is a human vaccine with investigational new drug status and is used as a prototype Venezuelan equine encephalitis virus for pathogenesis and antiviral research. Differing from other experimental models, the virus causes high titer infection in the brain and 90-100{\%} mortality in the C3H/HeN murine model. To better characterize the susceptibility to disease development in C3H/HeN mice, we have analyzed the gene transcriptomes and cytokine production in the brains of infected mice. Our analysis indicated the potential importance of natural killer cells in the encephalitic disease development. This paper describes for the first time a pathogenic role for natural killer cells in VEEV encephalitis.",
keywords = "Alphavirus, Encephalitis, Immunology, Natural killer cells, VEEV",
author = "Katherine Taylor and Olga Kolokoltsova and Michael Patterson and Allison Poussard and Jennifer Smith and Estes, {D. Mark} and Slobodan Paessler",
year = "2012",
month = "6",
day = "8",
doi = "10.1016/j.vaccine.2012.03.076",
language = "English (US)",
volume = "30",
pages = "4095--4105",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "27",

}

TY - JOUR

T1 - Natural killer cell mediated pathogenesis determines outcome of central nervous system infection with Venezuelan equine encephalitis virus in C3H/HeN mice

AU - Taylor, Katherine

AU - Kolokoltsova, Olga

AU - Patterson, Michael

AU - Poussard, Allison

AU - Smith, Jennifer

AU - Estes, D. Mark

AU - Paessler, Slobodan

PY - 2012/6/8

Y1 - 2012/6/8

N2 - TC83 is a human vaccine with investigational new drug status and is used as a prototype Venezuelan equine encephalitis virus for pathogenesis and antiviral research. Differing from other experimental models, the virus causes high titer infection in the brain and 90-100% mortality in the C3H/HeN murine model. To better characterize the susceptibility to disease development in C3H/HeN mice, we have analyzed the gene transcriptomes and cytokine production in the brains of infected mice. Our analysis indicated the potential importance of natural killer cells in the encephalitic disease development. This paper describes for the first time a pathogenic role for natural killer cells in VEEV encephalitis.

AB - TC83 is a human vaccine with investigational new drug status and is used as a prototype Venezuelan equine encephalitis virus for pathogenesis and antiviral research. Differing from other experimental models, the virus causes high titer infection in the brain and 90-100% mortality in the C3H/HeN murine model. To better characterize the susceptibility to disease development in C3H/HeN mice, we have analyzed the gene transcriptomes and cytokine production in the brains of infected mice. Our analysis indicated the potential importance of natural killer cells in the encephalitic disease development. This paper describes for the first time a pathogenic role for natural killer cells in VEEV encephalitis.

KW - Alphavirus

KW - Encephalitis

KW - Immunology

KW - Natural killer cells

KW - VEEV

UR - http://www.scopus.com/inward/record.url?scp=84861481663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861481663&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.03.076

DO - 10.1016/j.vaccine.2012.03.076

M3 - Article

VL - 30

SP - 4095

EP - 4105

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 27

ER -